BioOrbit is a biotechnology company specialising in the in-space manufacturing of pharmaceutical drugs, particularly focusing on the crystallisation of protein-based therapies in microgravity environments. By leveraging the unique conditions of space, BioOrbit aims to produce high-purity protein crystals, facilitating the development of subcutaneous formulations for treatments traditionally administered intravenously. This innovation seeks to transform hospital-based therapies into at-home injectables, enhancing patient accessibility and convenience. Founded in 2023, BioOrbit is at the forefront of integrating space technology with pharmaceutical manufacturing to revolutionise drug delivery methods.
